MTOR and hepatocellular carcinoma: The two study groups had no significant differences concerning age, hypertension, clinical ascites, immunosuppressive agents (such as mTOR inhibitors), ALBI scores, liver diseases (i.e., HCV and HCC), MELD-Na score, pretransplant albumin and hematocrit, obesity, blood loss during LT, postoperative infection, abdominal reoperation in 3 months after LT, or suture material for closure (Table 1).